Endo International, PLC, a
subsidiary of Par Pharmaceutical, recently released mycophenolate mofetil hydrochloride (HCI) in the U.S. following Food and Drug Administration approval of its Abbreviated New Drug Application.
HCI, an injection that will
be sold in cartons containing four 500 mg single dose vials, is the generic
form of CellCept. Upon release, it will be the only generic injection on the
market.
CellCept, a registered trademark of Hoffman-LaRoche Inc., is used to
prevent rejection of a kidney, liver or heart transplant. According to
numbers from IMS Health, CellCept recorded roughly $42 million in U.S. sales
during the 12-month period that ended Oct. 31.
Endo International releases HCI generic injection drug in U.S.
Alerts Sign-up